应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02160 心通医疗-B
国庆日翌日休市 09-29 16:08:22
1.670
-0.090
-5.11%
最高
1.770
最低
1.620
成交量
150.30万
今开
1.770
昨收
1.760
日振幅
8.52%
总市值
40.29亿
流通市值
40.29亿
总股本
24.12亿
成交额
250.91万
换手率
0.06%
流通股本
24.12亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
心通医疗-B盘中异动 早盘股价大跌5.11%报1.670港元
自选股智能写手 · 09-29
心通医疗-B盘中异动 早盘股价大跌5.11%报1.670港元
智通港股通资金流向统计(T+2)|9月28日
智通财经 · 09-28
智通港股通资金流向统计(T+2)|9月28日
心通医疗-B盘中异动 早盘急速拉升5.03%
自选股智能写手 · 09-27
心通医疗-B盘中异动 早盘急速拉升5.03%
心通医疗-B(02160.HK):9月21日南向资金增持26.4万股
证券之星 · 09-22
心通医疗-B(02160.HK):9月21日南向资金增持26.4万股
智通港股通资金流向统计(T+2)|9月6日
智通财经 · 09-06
智通港股通资金流向统计(T+2)|9月6日
心通医疗-B(02160.HK):9月5日南向资金增持269.8万股
证券之星 · 09-06
心通医疗-B(02160.HK):9月5日南向资金增持269.8万股
心通医疗-B(02160.HK):上半年符合预期 期待TAVR持续放量
中金公司 · 09-05
心通医疗-B(02160.HK):上半年符合预期 期待TAVR持续放量
港股异动 | 心通医疗-B(02160)跌超5% 上半年亏损同比扩大46.59%至1.79亿元
智通财经 · 08-31
港股异动 | 心通医疗-B(02160)跌超5% 上半年亏损同比扩大46.59%至1.79亿元
心通医疗-B(02160)授出400万份购股权
智通财经网 · 08-30
心通医疗-B(02160)授出400万份购股权
心通医疗-B(02160)发布中期业绩 股东应占亏损1.79亿元 同比扩大46.59%
智通财经 · 08-29
心通医疗-B(02160)发布中期业绩 股东应占亏损1.79亿元 同比扩大46.59%
心通医疗-B(02160):Jeffrey R Lindstrom获委任为执行董事、总裁及上海微创心通的董事兼总经理
智通财经 · 08-29
心通医疗-B(02160):Jeffrey R Lindstrom获委任为执行董事、总裁及上海微创心通的董事兼总经理
心通医疗-B(02160.HK):8月21日南向资金增持8.5万股
证券之星 · 08-22
心通医疗-B(02160.HK):8月21日南向资金增持8.5万股
心通医疗-B(02160.HK)8月29日举行董事会会议考虑及批准中期业绩
格隆汇资讯 · 08-17
心通医疗-B(02160.HK)8月29日举行董事会会议考虑及批准中期业绩
港股异动 | 爱康医疗(01789)跌近6%领跌医疗器械股 机构称高值耗材短期受一定影响
智通财经 · 08-15
港股异动 | 爱康医疗(01789)跌近6%领跌医疗器械股 机构称高值耗材短期受一定影响
心通医疗-B盘中异动 急速下跌5.05%报1.900港元
自选股智能写手 · 08-15
心通医疗-B盘中异动 急速下跌5.05%报1.900港元
心通医疗-B(02160.HK):8月7日南向资金增持97.3万股
证券之星 · 08-08
心通医疗-B(02160.HK):8月7日南向资金增持97.3万股
心通医疗-B盘中异动 早盘股价大跌5.21%
自选股智能写手 · 08-07
心通医疗-B盘中异动 早盘股价大跌5.21%
心通医疗:自研经导管二尖瓣置换系统多例人体植入随访结果优异
国际金融报 · 08-06
心通医疗:自研经导管二尖瓣置换系统多例人体植入随访结果优异
心通医疗-B(02160.HK):自研经导管二尖瓣置换系统多例人体植入随访结果优异
市场资讯 · 08-06
心通医疗-B(02160.HK):自研经导管二尖瓣置换系统多例人体植入随访结果优异
心通医疗-B(02160.HK):出海在即 创新型心脏瓣膜介入诊疗平台
华安证券 · 08-04
心通医疗-B(02160.HK):出海在即 创新型心脏瓣膜介入诊疗平台
加载更多
公司概况
公司名称:
心通医疗-B
所属市场:
SEHK
上市日期:
--
主营业务:
微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要产品包括第一代经导管主动脉瓣植入(TAVI)产 品“VitaFlow”和第二代TAVI产品“VitaFlow II”。该公司主要于国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02160","market":"HK","secType":"STK","nameCN":"心通医疗-B","latestPrice":1.67,"timestamp":1695974902030,"preClose":1.76,"halted":0,"volume":1503000,"delay":0,"floatShares":2412383588,"shares":2412383588,"eps":-0.20604824,"marketStatus":"国庆日翌日休市","marketStatusCode":7,"change":-0.09,"latestTime":"09-29 16:08:22","open":1.77,"high":1.77,"low":1.62,"amount":2509110,"amplitude":0.085227,"askPrice":1.68,"askSize":7000,"bidPrice":1.67,"bidSize":74000,"shortable":3,"etf":0,"ttmEps":-0.2325110435790595,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1696296600000},"adr":0,"listingDate":1612368000000,"adjPreClose":1.76,"volumeRatio":1.0032038446135363,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02160","defaultTab":"news","newsList":[{"id":"2371703899","title":"心通医疗-B盘中异动 早盘股价大跌5.11%报1.670港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2371703899","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2371703899?lang=zh_cn&edition=full","pubTime":"2023-09-29 09:47","pubTimestamp":1695952057,"startTime":"0","endTime":"0","summary":"2023年09月29日早盘09时47分,心通医疗-B股票出现异动,股价大幅下挫5.11%。截至发稿,该股报1.670港元/股,成交量41.5万股,换手率0.02%,振幅5.68%。资金方面,该股资金流入0港元,流出64.373万港元。心通医疗-B股票所在的医疗设备及用品行业中,整体跌幅为0.01%。其相关个股中,智云健康、中国卫生集团、润迈德-B涨幅较大,振幅较大的相关个股有佳兆业健康、心通医疗-B、归创通桥-B,振幅分别为10.00%、5.68%、4.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023092909473782f7ae17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023092909473782f7ae17&s=b","is_publish_highlight":false},{"id":"2370711339","title":"智通港股通资金流向统计(T+2)|9月28日","url":"https://stock-news.laohu8.com/highlight/detail?id=2370711339","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2370711339?lang=zh_cn&edition=full","pubTime":"2023-09-28 07:30","pubTimestamp":1695857458,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,9月25日,盈富基金、恒生中国企业、南方恒生科技南向资金净流入金额位列市场前三,分别净流入16.71 亿、7.77 亿、6.21 亿中国移动、中国海洋石油、腾讯控股南向资金净流出金额位列市场前三,分别净流出-5.28 亿、-3.13 亿、-2.16 亿在净流入比方面,中船防务、青岛银行、渤海银行以85.69%、84.87%、81.62%位列市场前三。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1000939.html","is_publish_highlight":false},{"id":"2370787740","title":"心通医疗-B盘中异动 早盘急速拉升5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2370787740","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2370787740?lang=zh_cn&edition=full","pubTime":"2023-09-27 09:38","pubTimestamp":1695778716,"startTime":"0","endTime":"0","summary":"2023年09月27日早盘09时38分,心通医疗-B股票出现异动,股价快速拉升5.03%。截至发稿,该股报1.880港元/股,成交量21.1万股,换手率0.01%,振幅3.35%。机构评级方面,在所有6家参与评级的机构中,83%的券商给予买入建议,17%的券商给予持有建议,无券商给予卖出建议。其相关个股中,心通医疗-B、启明医疗-B、威高股份涨幅较大,振幅较大的相关个股有佳兆业健康、中国卫生集团、威高股份,振幅分别为11.43%、4.17%、3.92%。该公司主要于国内市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927093836838efa1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230927093836838efa1d&s=b","is_publish_highlight":false},{"id":"2369433416","title":"心通医疗-B(02160.HK):9月21日南向资金增持26.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2369433416","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2369433416?lang=zh_cn&edition=full","pubTime":"2023-09-22 05:51","pubTimestamp":1695333100,"startTime":"0","endTime":"0","summary":"近20个交易日中,获南向资金增持的有17天,累计净增持1628.0万股。截至目前,南向资金持有心通医疗-B2.11亿股,占公司已发行普通股的8.72%。微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要于国内市场开展业务。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230922055152825f3fc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230922055152825f3fc1&s=b","is_publish_highlight":false},{"id":"2365096484","title":"智通港股通资金流向统计(T+2)|9月6日","url":"https://stock-news.laohu8.com/highlight/detail?id=2365096484","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2365096484?lang=zh_cn&edition=full","pubTime":"2023-09-06 07:30","pubTimestamp":1693956658,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,8月31日,工商银行、中国海洋石油、美团-W南向资金净流入金额位列市场前三,分别净流入3.84 亿、3.24 亿、3.13 亿腾讯控股、李宁、东方甄选南向资金净流出金额位列市场前三,分别净流出-4.94 亿、-1.18 亿、-9711.01 万在净流入比方面,高视医疗、复旦张江、海普瑞以94.17%、72.22%、62.24%位列市场前三。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/991315.html","is_publish_highlight":false},{"id":"2365398067","title":"心通医疗-B(02160.HK):9月5日南向资金增持269.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2365398067","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2365398067?lang=zh_cn&edition=full","pubTime":"2023-09-06 03:41","pubTimestamp":1693942902,"startTime":"0","endTime":"0","summary":"近5个交易日中,获南向资金增持的有5天,累计净增持419.6万股。截至目前,南向资金持有心通医疗-B2.04亿股,占公司已发行普通股的8.45%。微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要于国内市场开展业务。以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230906034225822e4a33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230906034225822e4a33&s=b","is_publish_highlight":false},{"id":"2365080528","title":"心通医疗-B(02160.HK):上半年符合预期 期待TAVR持续放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2365080528","media":"中金公司","top":-1,"share":"https://www.laohu8.com/m/news/2365080528?lang=zh_cn&edition=full","pubTime":"2023-09-05 13:51","pubTimestamp":1693893100,"startTime":"0","endTime":"0","summary":"上半年业绩符合我们的预期。发展趋势TAVR 手术强势增长,公司份额持续提升。公司表示上半年国内TAVR 植入量1,923 台,同比+50%。1H23 毛利率提升2.4 ppt,公司表示主要得益于供方的多样化开发、本地化的原材料采购、原材料合格率提升以及制造工艺的优化。公司也预计三代TAVR 上市后有望进一步显著提升毛利率。截至1H23,公司在手的现金和现金等价物尚有20 亿元。二尖瓣缘对缘修复装置处于动物试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230905135141822c3027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230905135141822c3027&s=b","is_publish_highlight":false},{"id":"2363250463","title":"港股异动 | 心通医疗-B(02160)跌超5% 上半年亏损同比扩大46.59%至1.79亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2363250463","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2363250463?lang=zh_cn&edition=full","pubTime":"2023-08-31 14:46","pubTimestamp":1693464381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,心通医疗-B(02160)跌超5%,截至发稿,跌5.24%,报1.81港元,成交额384.05万港元。消息面上,心通医疗发布截至2023年6月30日止六个月的未经审核中期业绩,该集团期内取得收入1.76亿元(人民币,下同),同比增加41.4%;股东应占亏损1.79亿元,同比扩大46.59%;每股基本亏损0.08元。公告称,收入增加主要是由于集团的TAVI产品入院的持续进展及海外强劲增长所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/988896.html","is_publish_highlight":false},{"id":"2363404596","title":"心通医疗-B(02160)授出400万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2363404596","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2363404596?lang=zh_cn&edition=full","pubTime":"2023-08-30 22:07","pubTimestamp":1693404450,"startTime":"0","endTime":"0","summary":"心通医疗-B(02160)发布公告,于2023年8月30日,公司已决议根据公司于2...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_34.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_34.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/988467.html","is_publish_highlight":false},{"id":"2363149552","title":"心通医疗-B(02160)发布中期业绩 股东应占亏损1.79亿元 同比扩大46.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2363149552","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2363149552?lang=zh_cn&edition=full","pubTime":"2023-08-29 23:05","pubTimestamp":1693321516,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心通医疗-B(02160)发布截至2023年6月30日止六个月的未经审核中期业绩,该集团期内取得收入1.76亿元(人民币,下同),同比增加41.4%;股东应占亏损1.79亿元,同比扩大46.59%;每股基本亏损0.08元。公告称,收入增加主要是由于集团的TAVI产品入院的持续进展及海外强劲增长所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230829230703844165de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230829230703844165de&s=b","is_publish_highlight":false},{"id":"2363498209","title":"心通医疗-B(02160):Jeffrey R Lindstrom获委任为执行董事、总裁及上海微创心通的董事兼总经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2363498209","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2363498209?lang=zh_cn&edition=full","pubTime":"2023-08-29 22:35","pubTimestamp":1693319718,"startTime":"0","endTime":"0","summary":"智通财经APP讯,心通医疗-B(02160)发布公告,自2023年8月29日起,罗七一已辞任非执行董事、主席、提名委员会主席、薪酬委员会成员、授权代表及上海微创心通的董事兼主席; 陈国明已辞任总裁及上海微创心通的总经理及由执行董事调任为非执行董事,并已获委任为主席、提名委员会主席、薪酬委员会成员、授权代表及上海微创心通的主席;及Jeffrey R Lindstrom已获委任为执行董事、总裁及上海微创心通的董事兼总经理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/986896.html","is_publish_highlight":false},{"id":"2361504747","title":"心通医疗-B(02160.HK):8月21日南向资金增持8.5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2361504747","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2361504747?lang=zh_cn&edition=full","pubTime":"2023-08-22 05:11","pubTimestamp":1692652292,"startTime":"0","endTime":"0","summary":"近20个交易日中,获南向资金增持的有19天,累计净增持2285.8万股。截至目前,南向资金持有心通医疗-B1.94亿股,占公司已发行普通股的8.02%。微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要于国内市场开展业务。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082205222181fd0d83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023082205222181fd0d83&s=b","is_publish_highlight":false},{"id":"2360360163","title":"心通医疗-B(02160.HK)8月29日举行董事会会议考虑及批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2360360163","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2360360163?lang=zh_cn&edition=full","pubTime":"2023-08-17 16:46","pubTimestamp":1692262013,"startTime":"0","endTime":"0","summary":"格隆汇8月17日丨心通医疗-B(02160.HK)宣布,公司将于2023年8月29日(星期二)举行董事会会议,以考虑及批准(其中包括)公司及其附属公司截至2023年6月30日止六个月之中期业绩及其发布,以及派发中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023081716472481f17bd4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023081716472481f17bd4&s=b","is_publish_highlight":false},{"id":"2359086119","title":"港股异动 | 爱康医疗(01789)跌近6%领跌医疗器械股 机构称高值耗材短期受一定影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2359086119","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2359086119?lang=zh_cn&edition=full","pubTime":"2023-08-15 10:57","pubTimestamp":1692068271,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,医疗器械股早盘继续走低,截至发稿,爱康医疗(01789)跌5.94%,报5.7港元;心通医疗-B(02160)跌4.5%,报1.91港元;微创脑科学(02172)跌3.44%,报11.78港元;微创医疗(00853)跌2.78%,报13.78港元。消息面上,中信建投表示,医疗反腐或对各细分领域产生不同的影响。高值耗材方面,部分新产品进院流程及学术推广短期有可能受到一定影响,但临床价值明确、临床需求刚性的产品预计受到影响较小。低值耗材方面,低值耗材的经销商利润空间相对不大,预计受反腐影响相对较小,目前整体估值水平处于较低位置,部分低值耗材公司出口迎来拐点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/975566.html","is_publish_highlight":false},{"id":"2359486678","title":"心通医疗-B盘中异动 急速下跌5.05%报1.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2359486678","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2359486678?lang=zh_cn&edition=full","pubTime":"2023-08-15 10:11","pubTimestamp":1692065465,"startTime":"0","endTime":"0","summary":"2023年08月15日早盘10时11分,心通医疗-B股票出现异动,股价大幅跳水5.05%。截至发稿,该股报1.900港元/股,成交量110.9万股,换手率0.05%,振幅5.00%。心通医疗-B股票所在的医疗保健设备行业中,整体跌幅为0.08%。其相关个股中,华检医疗、中国再生医学、HKE HOLDINGS涨幅较大,振幅较大的相关个股有华检医疗、微创脑科学、HKE HOLDINGS,振幅分别为17.70%、7.21%、6.30%。消息层面,截至10时11分,心通医疗-B股票正面舆情新闻比例100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023081510110582ea64e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023081510110582ea64e9&s=b","is_publish_highlight":false},{"id":"2357501212","title":"心通医疗-B(02160.HK):8月7日南向资金增持97.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2357501212","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2357501212?lang=zh_cn&edition=full","pubTime":"2023-08-08 04:11","pubTimestamp":1691439096,"startTime":"0","endTime":"0","summary":"近20个交易日中,获南向资金增持的有18天,累计净增持3439.3万股。截至目前,南向资金持有心通医疗-B1.85亿股,占公司已发行普通股的7.65%。微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要于国内市场开展业务。证券之星力求但不保证该信息全部或者部分内容的的准确性、完整性、有效性、及时性等,如存在问题请联系我们。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230808041204826fac07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230808041204826fac07&s=b","is_publish_highlight":false},{"id":"2357403226","title":"心通医疗-B盘中异动 早盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2357403226","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2357403226?lang=zh_cn&edition=full","pubTime":"2023-08-07 10:24","pubTimestamp":1691375090,"startTime":"0","endTime":"0","summary":"2023年08月07日早盘10时24分,心通医疗-B股票出现异动,股价急速下挫5.21%。截至发稿,该股报2.001港元/股,成交量139.501万股,换手率0.06%,振幅5.21%。心通医疗-B股票所在的医疗保健设备行业中,整体跌幅为0.31%。其相关个股中,高视医疗、健世科技-B、中国卫生集团涨幅较大,振幅较大的相关个股有诺辉健康、爱康医疗、启明医疗-B,振幅分别为11.16%、9.68%、7.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023080710245082e79fea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023080710245082e79fea&s=b","is_publish_highlight":false},{"id":"2357429565","title":"心通医疗:自研经导管二尖瓣置换系统多例人体植入随访结果优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2357429565","media":"国际金融报","top":-1,"share":"https://www.laohu8.com/m/news/2357429565?lang=zh_cn&edition=full","pubTime":"2023-08-06 19:16","pubTimestamp":1691320565,"startTime":"0","endTime":"0","summary":"心通医疗港交所公告,集团自主研发的经导管二尖瓣置换系统正推进临床应用,并已成功用于救治多名重度二尖瓣反流患者,其中首例患者于近日顺利完成一年随访,其余患者的3个月、一个月随访结果亦令人振奋,均实现二尖瓣反流显著降低、无反复,无瓣周漏,无左室流出道梗阻,心功能相关指标明显改善,患者自述二尖瓣反流引起的不适症状明显好转。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230806191618837f895d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230806191618837f895d&s=b","is_publish_highlight":false},{"id":"2357582426","title":"心通医疗-B(02160.HK):自研经导管二尖瓣置换系统多例人体植入随访结果优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2357582426","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2357582426?lang=zh_cn&edition=full","pubTime":"2023-08-06 18:22","pubTimestamp":1691317326,"startTime":"0","endTime":"0","summary":"我们的经导管二尖瓣置换系统是全球首个应用于临床的干瓣经导管二尖瓣置换产品,其多例成功人体应用及优异随访结果进一步验证该系统的有效性及安全性,标志着该系统的临床应用迈入新阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-08-06/doc-imzfheuy1256790.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-08-06/doc-imzfheuy1256790.shtml","is_publish_highlight":false},{"id":"2356480663","title":"心通医疗-B(02160.HK):出海在即 创新型心脏瓣膜介入诊疗平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2356480663","media":"华安证券","top":-1,"share":"https://www.laohu8.com/m/news/2356480663?lang=zh_cn&edition=full","pubTime":"2023-08-04 17:01","pubTimestamp":1691139703,"startTime":"0","endTime":"0","summary":"心脏瓣膜赛道持续高增长,微创趋势催化介入瓣放量结构性心脏病赛道是未来十年的黄金赛道。“老龄化趋势+微创治疗理念”催生瓣膜介入手术量高速增长。支付端改善明显,TAVR 赛道渐入佳境,公司引领行业增长今年以来,全国新增多省将TAVR 耗材费用纳入医保,目前总计超过10省,支付端出现重大改善。3)TAVR 产品预计2023 年底获批CE 证,进一步扩大海外市场。已完成首例植入及6 个月随访,预计今年完成全部FIM 入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308041701488268a9aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202308041701488268a9aa&s=b","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0457},{"period":"1month","weight":-0.1257},{"period":"3month","weight":-0.0565},{"period":"6month","weight":-0.2802},{"period":"1year","weight":-0.2707},{"period":"ytd","weight":-0.3602}],"websiteUrl":null,"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0364},{"period":"3month","weight":-0.0585},{"period":"6month","weight":-0.127},{"period":"1year","weight":0.0375},{"period":"ytd","weight":-0.0997}],"name":"心通医疗-B","description":"微创心通医疗科技有限公司是一家主要从事医疗器械行业的中国投资控股公司。该公司主要从事心脏瓣膜疾病领域经导管及手术解决方案的研发和商业化。该公司主要产品包括第一代经导管主动脉瓣植入(TAVI)产 品“VitaFlow”和第二代TAVI产品“VitaFlow II”。该公司主要于国内市场开展业务。","exchange":"SEHK","nameEN":"CARDIOFLOW-B","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.17.2","shortVersion":"4.17.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"心通医疗-B(02160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供心通医疗-B(02160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"心通医疗-B,02160,心通医疗-B股票,心通医疗-B股票老虎,心通医疗-B股票老虎国际,心通医疗-B行情,心通医疗-B股票行情,心通医疗-B股价,心通医疗-B股市,心通医疗-B股票价格,心通医疗-B股票交易,心通医疗-B股票购买,心通医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"心通医疗-B(02160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供心通医疗-B(02160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}